Phio Pharmaceutical

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PHIO and other ETFs, options, and stocks.

About PHIO

Phio Pharmaceuticals Corp. is a biotechnology company engaged in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries.

CEO

Geert Cauwenbergh, PhD

CEOGeert Cauwenbergh, PhD

Employees

Employees12

Headquarters

Marlborough, Massachusetts

HeadquartersMarlborough, Massachusetts

Founded

2011

Founded2011

Employees

Employees12

PHIO Key Statistics

Market cap

7.09M

Market cap7.09M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

48.74K

Average volume48.74K

High today

$6.54

High today$6.54

Low today

$6.13

Low today$6.13

Open price

$6.20

Open price$6.20

Volume

14.40K

Volume14.40K

52 Week high

$29.04

52 Week high$29.04

52 Week low

$3.90

52 Week low$3.90

PHIO Earnings

-$3.36

-$2.24

-$1.12

-$0.00

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Mar 21, After Hours

ActualExpected Mar 21, After Hours

Phio Pharmaceutical

Why Robinhood?

Phio Pharmaceuticals Corp. is a biotechnology company engaged in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. Show more

PHIO Key Statistics

Phio Pharmaceuticals Corp. is a biotechnology company engaged in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries.